ProCE Banner Activity

Role of PARP Inhibitor Maintenance Therapy in Newly Diagnosed Ovarian Cancer

Slideset Download

In this downloadable slideset, CCO’s expert faculty reviews current clinical use of PARP inhibitors in the treatment of patients with newly diagnosed ovarian cancer.

This slideset is intended for clinicians practicing medicine outside of the United States.

Released: December 17, 2020

Expiration: December 16, 2021

No longer available for credit.

Share

Faculty

Antonio Gonzalez-Martin

Antonio Gonzalez-Martin, MD, PhD

Head, Medical Oncology
Co-Director, Oncology Department
Oncology Department, Medical Oncology Service
Clinica Universidad Navarra
Madrid, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Antonio Gonzalez-Martin, MD, PhD

Head, Medical Oncology
Co-Director, Oncology Department
Oncology Department, Medical Oncology Service
Clinica Universidad Navarra
Madrid, Spain